Article

Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myeloma

2025-10-10

Abstract excerpt

<title>Abstract</title> <p>These findings demonstrate Nb17-nanoCAR-T exhibits potent anti-myeloma efficacy comparable to scFv-based CAR-T, supporting its potential as a promising therapeutic alternative. Multiple myeloma (MM) is an incurable hematologic malignancy arising from clonal plasma cells, with poor long-term outcomes due to inevitable relapse after conventional therapies. Chimeric antigen receptor (CAR)...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 421b08dc-83e1-5142-a75d-33daa242f02a
DOI: 10.21203/rs.3.rs-7693534/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myelomaDOI 10.21203/rs.3.rs-7693534/v1Read

CAR T-cell therapy in multiple myeloma: mission accomplished?Semantic proximity Read

BCMA/CD19 dual-targeting with FasTCAR: AZD0120 demonstrates potent preclinical efficacy in multiple myelomaSemantic proximity Read

Rational engineering of sdAb-based CAR T cells targeting BCMA enhances antitumor efficacy and persistence in Multiple MyelomaSemantic proximity Read

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaSemantic proximity Read

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myelomaSemantic proximity Read

Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple MyelomaSemantic proximity Read

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple MyelomaSemantic proximity Read

Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cellsSemantic proximity Read

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaSemantic proximity Read

Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple MyelomaSemantic proximity Read

Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cellsSemantic proximity Read

Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and ResistanceSemantic proximity Read